All sponsors

Abbisko Therapeutics Co, Ltd

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS11
PHASE 3 / 2-31
RECRUITING6
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO40%

Delay Index: of 5 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Abbisko Therapeutics Co, Ltd on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Pimicotinib(ABSK021)
NCT05804045
P3Active, not recruitingTenosynovial Giant Cell Tumor; Pigmented Villonodular Synovitis942024-09-23 (-19 mo)
Pimicotinib (ABSK021)
NCT06111274
P2RecruitingAdvanced Pancreatic Cancer822025-12-30
ABSK021
NCT06186804
P2Enrolling by invitationcGvHD642026-10-30
ABSK-011+BSC
NCT07327034
P2RecruitingHepatocellular Carcinoma (HCC)1412027-06-30
ABSK043 in combination with Firmonertinib
NCT06668103
P2RecruitingNon-Small Cell Lung Cancer With EGFR Mutation542027-12-30 (+6 mo)
ABSK061
NCT07297875
P1/2Not yet recruitingAchondroplasia1102028-12-15
ABSK043 in combination with Glecirasib
NCT07164170
P2RecruitingNon-Small Cell Lung Cancer862028-12-30
ABSK141-400mg
NCT07417189
P1/2RecruitingSolid Tumors, Adult4012028-12-30
ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w
NCT05441475
P2Enrolling by invitationHepatocellular Carcinoma1182028-12-31 (+53 mo)
ABSK061 + ABSK043
NCT06632262
P2RecruitingHER2-Gastric/Gastroesophageal Junction Cancer; Urothelial Carcinoma2022029-11-30
ABSK043 in combination with Osimertinib
NCT07710612
P2Not yet recruitingNon-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive722029-12-31